Executive record

Sir Michael Houghton, Ph.D.

Director at ASSEMBLY BIOSCIENCES, INC.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:sir-michael-houghton-ph-dVersion: public-0As of: 2026-09-30

Not yet claimed11 published Claims4 sources
  • Director

Key Claims

Biography

Sir Michael Houghton is the La Ka Shing Professor in the Department of Medical Microbiology and Immunology at the University of Alberta since 2010 and director of the La Ka Shing Applied Virology Institute. He was jointly awarded the 2020 Nobel Prize in Physiology or Medicine for the discovery of hepatitis C virus. He has extensive pharmaceutical industry experience and serves as CEO of Aurora Vaccines Inc. and Chief Scientific Officer at Applied Pharmaceutical Innovation.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Director · Organization not publishedASMB DEF 14A executive officers
  2. Dates not publishedExecutive title: Chief Scientific Officer · Organization not publishedASMB DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ASMB DEF 14A director slate

    sec filing · Source published: Apr 22, 2026 · Retrieved: May 15, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Science/Innovation · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Applied Pharmaceutical Innovation · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Scientific Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. ASMB DEF 14A executive officers

    sec filing · Source published: Apr 22, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at ASSEMBLY BIOSCIENCES, INC. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  3. Open source

    sec proxy · Source published: Apr 22, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at ASSEMBLY BIOSCIENCES, INC. · Claim reviewed: May 15, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of ASSEMBLY BIOSCIENCES, INC. · Claim reviewed: May 15, 2026